Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma of Lung (Phase 2)
Ascites (Phase 1/Phase 2)
Bevacizumab (Phase 2/Phase 3)
Brain Neoplasms (Phase 2/Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Neuroendocrine (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
DNA Mismatch Repair (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 3)
Hepatitis B, Chronic (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immunotherapy (Phase 2/Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Triple Negative Breast Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
Vascular Endothelial Growth Factor A (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue